Inhibrx INBX Investor Presentation September 2023

Inhibrx is a clinical-stage biopharmaceutical company focused on discovering and developing effective biologic treatments for life-threatening conditions using proprietary protein engineering. The company, founded in 2010 and publicly listed in 2020, has 165+ employees and maintains a differentiated pipeline of next-generation therapeutics across focused disease areas.